Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 17/20 | 0.62 |
| ▸ | NQO2 | P16083 | 1/20 | 0.62 |
| ▸ | CSF1R | P07333 | 1/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | NEK2 | P51955 | 1/20 | 0.38 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.38 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.38 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12760969 | 0.90 | MET (0.78) | METNQO2 | |
| SCHEMBL12857962 | 0.89 | MET (0.59) | METNQO2CSF1R | |
| SCHEMBL1151165 | 0.84 | MET (0.63) | METNQO2 | |
| SCHEMBL12968371 | 0.80 | MET (0.48) | METCHEK1NEK2LIMK1TYRO3 | |
| SCHEMBL3088622 | 0.80 | MET (0.80) | METNQO2 | |
| SCHEMBL12870216 | 0.78 | MET (0.61) | METNQO2 | |
| SCHEMBL13284134 | 0.78 | MET (0.80) | METNQO2 | |
| SCHEMBL2457792 | 0.78 | MET (0.80) | METNQO2 | |
| SCHEMBL12857964 | 0.78 | MET (0.47) | METNQO2 | |
| SCHEMBL2455548 | 0.77 | MET (0.79) | METNQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8604036-B2 | Pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2013-12-10 | — | — | US | claimed |
| US-20110034474-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-02-10 | — | — | US | claimed |
| US-8604036-B2 | Pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2013-12-10 | — | — | US | disclosed |
| US-20110034474-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-02-10 | — | — | US | disclosed |
| EP-2280962-A1 | PYRIDAZINONE DERIVATIVES | Merck Patent GmbH (DE) | 2011-02-09 | — | — | EP | disclosed |
| WO-2009129905-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034474-A1 | PYRIDAZINONE DERIVATIVES | MET, ERBB2, BRAF | MET 1/4885NQO2 588/4885CSF1R 873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.